<p>Cardiff Oncology Inc. has announced that clinical data from an investigator-sponsored trial of onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting. The presentation is scheduled for December 8, 2025. The abstract related to this trial is available on the ASH Annual Meeting website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598742-en) on December 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CRDF

<p>Cardiff Oncology Inc. announced that new clinical data from a trial of onvansertib in chronic myelomonocytic leukemia will be presented at the 67th American Society of Hematology Annual Meeting on December 8, 2025. The abstract is available on the ASH website. This information was originally published by Cardiff Oncology via GlobeNewswire.</p>

Cardiff Oncology Announces New Clinical Data on Onvansertib in Chronic Myelomonocytic Leukemia